NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) today announced the release of a white paper titled “StereoCED™ - A Scalable Platform for CNS Drug Delivery,” available on the Scientific Resources section of nmtc1.com. The paper outlines how the company’s StereoCED™ platform is being designed to overcome key barriers to commercializing brain-delivered therapeutics, including cell and gene therapies, biologics, and other central nervous system (CNS) treatments.
As advances in CNS therapeutics increase demand for efficient drug delivery methods, convection-enhanced delivery (CED) has shown promise in bypassing the blood-brain barrier and achieving targeted distribution. However, current CED approaches may present challenges as therapies expand into broader commercial use, including lengthy infusion procedures lasting 8 to 12 hours. The StereoCED™ platform leverages robotic stereotactic systems already established in neurosurgical operating rooms to support simultaneous, multi-trajectory intracranial drug delivery through a streamlined robotic workflow. This approach is designed to significantly reduce procedure time while enabling reproducible, scalable therapeutic delivery.
“Brain-delivered therapeutics are approaching an important inflection point,” said Dave Rosa, President and Chief Executive Officer of NeuroOne. “As these therapies move toward commercialization, certain intracranial infusion procedures lasting 8 to 12 hours may become a significant bottleneck to commercial adoption. We believe healthcare systems will need solutions that leverage established neurosurgical workflows, significantly reduce procedure time, and support scalable delivery across hospitals. StereoCED™ is being designed with those needs in mind, and we look forward to device availability for research and investigational clinical studies by fiscal year-end.”
The white paper highlights that the platform is still under development and has not been cleared or approved by the U.S. Food and Drug Administration for commercialization. However, device availability for research and investigational clinical studies is expected by the end of NeuroOne’s fiscal year. The company believes that by integrating with existing robotic systems, StereoCED™ can reduce the need for specialized workflows and lengthy sequential infusions, potentially lowering costs and improving patient access to advanced CNS therapies.
This announcement comes as the CNS drug delivery market faces increasing pressure to develop scalable solutions. The ability to deliver therapeutics directly to the brain in a reproducible, time-efficient manner could accelerate the adoption of new treatments for neurological disorders such as Parkinson’s disease, brain tumors, and genetic conditions. For healthcare systems, shorter procedure times could translate to higher throughput and reduced operational burdens, while patients may benefit from expanded access to innovative therapies.
NeuroOne is a medical technology company focused on improving surgical care for neurological disorders. The company markets four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. Its ongoing research and development programs include drug delivery, basivertebral nerve ablation, and spinal cord stimulation.
